Výsledky vyhledávání - "J. P. Letzer"

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC)

Autor: Robert C. Hermann, John Nemunaitis, J. P. Letzer, Svetislava J. Vukelja, D. Richards, L. Gardner, L. T. Campos, Johanna C. Bendell, Christopher Hagenstad, Peter Sportelli

Publikováno v: Journal of Clinical Oncology. 28:3531-3531

3531 Background: Perifosine (P), a synthetic alkylphospholipid, inhibits or modifies signal transduction pathways including AKT, MAPK and JNK. We previously reported initial results of a phase II r...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e426a2b85d89a54a050dc5ac039e9acf
https://doi.org/10.1200/jco.2010.28.15_suppl.3531

Zobrazit plný text záznamu

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer

Autor: C. Bedell, L. T. Campos, Svetislava J. Vukelja, Donald A. Richards, J. P. Letzer, William J. Hyman, Peter Sportelli, L. Gardner, John Nemunaitis, Christopher Hagenstad

Publikováno v: Journal of Clinical Oncology. 27:4081-4081

4081 Background: Perifosine (Peri), a synthetic alkylphospholipid, inhibits or modifies a number of different signal transduction pathways (AKT, MAPK and JNK). Peri as a single agent or in combination with other cytotoxic agents, has shown clinical b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6bb55f0a4708f86ea41e01d9f54daeb
https://doi.org/10.1200/jco.2009.27.15_suppl.4081

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání